John Kerr posted in clinical trial • immunisation • meningitis • meningococcal B • vaccine on January 19th, 2012.
The MeNZB vaccine developed to control New Zealand’s meningococcal B epidemic in 2004-5 has helped researchers to create another, more advanced vaccine targeting more variants of the bacterial pathogen. The MeNZB vaccine was a regionally specific vaccine for New Zealand targeting the B serotype of the bacteria Neisseria meningitidis, which cause meningococcal diseases, including meningitis. […]
Continue reading “NZ research included in meningococcal B universal vaccine”